CML cells derived from all analyzed CML patients (irrelevant to BCR-ABL mutation or TKI resistance) exhibit similar sensitivity to USP47 inhibition-induced cytotoxicity. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.